idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
HIRI researchers discover novel compound that inhibits the growth of tumor-associated Fusobacteria
Fusobacteria, which are part of the oral microbiome, are suspected of playing a role in cancer progression. Scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) are working on innovative strategies to inhibit the spread of these bacteria. Antisense molecules, which could serve as programmable, targeted antibiotics, show great promise. In a recent study, a research team led by Jörg Vogel identified a compound that effectively halts the growth of five Fusobacterium species. The findings were published today in the journal mBio.
The human oral microbiome consists of over 700 bacterial species from seven distinct phyla, including Fusobacterium nucleatum. However, this microbe is not limited to the oral cavity. It can also colonize other parts of our body—particularly tumor tissues in esophageal, colon, and breast cancer. There, Fusobacterium nucleatum has been linked to tumor growth and metastasis. Targeted inhibition of these and other fusobacteria could improve recovery prospects for cancer patients. But how can this be achieved? Scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a site of the Braunschweig Helmholtz Centre for Infection Research (HZI) in cooperation with the Julius-Maximilians-Universität Würzburg (JMU), have set out to answer this question.
“Fusobacteria have long been overlooked despite their clinical importance,” says Jörg Vogel, Director of the HIRI and corresponding author of the study. “One of the goals of my research group at the HIRI is to explore strategies that can specifically eliminate these bacteria in carcinomas.”
Custom-made antibiotics
Although conventional antibiotics can inhibit fusobacteria and thereby slow down tumor growth, their long-term use can cause undesirable side effects such as gastrointestinal problems due to a disrupted gut flora. This is because they attack not only harmful but also beneficial bacteria. To avoid these risks, scientists at the HIRI are developing new, targeted treatment strategies. In their current study, published the American Society for Microbiology journal mBio, they focus on peptide nucleic acid, or PNA. These are synthetic molecules similar to DNA or RNA. Unlike natural nucleic acids, the backbone of PNAs consists of a peptide-like structure instead of sugar and phosphate groups, which gives PNAs exceptional stability. The bases remain similar to those in DNA, allowing PNAs to target transcripts. As antisense molecules, PNAs bind to complementary messenger RNA (mRNA), blocking its function and inhibiting the production of essential proteins. This targeted action positions PNAs as a potential new generation of antibacterial agents.
An unexpected discovery
Surprisingly, the antisense molecules introduced to target specific genes failed to inhibit bacterial growth. However, the research team made an unexpected discovery: the control compound, FUS79, which did not target a specific transcript, exhibited strong activity against five fusobacterial strains without affecting other tested bacterial species. “The result was surprising because the compound does not work in the expected way for antisense nucleic acid chains, but instead has a novel mechanism,” explains Valentina Cosi, first author of the study and a doctoral student in Jörg Vogel's laboratory. “It seems to exert its effects by inducing membrane stress, destabilizing the bacterial cell membrane or impairing its function, though we still need to investigate this in more detail.” Vogel adds that “our next step is to decipher the very mechanism of this compound and optimize it further to enhance its effectiveness”.
The study lays the groundwork for the development of antisense therapeutics against Fusobacterium nucleatum and highlights the potential of this compound as a new strategy for more targeted antibiotics. The gained insights have the potential to accelerate further research in this field, which could ultimately improve cancer treatment outcomes.
Funding
Authors Valentina Cosi and Falk Ponath were supported by the Fellowship Program of the Würzburg Vogel Foundation Dr. Eckernkamp. The study was also supported by funds from the Gottfried Wilhelm Leibniz Prize of the German Research Foundation (DFG) to Jörg Vogel and the Rbiotics project in the Bavarian research network bayresq.net. The research was furthermore funded by the German Federal Ministry of Education and Research as part of the Cluster4Future program (to Linda Popella and Jörg Vogel) and by the DFG through the Collaborative Research Center DECIDE (to Jörg Vogel).
This press release is also available on our website: https://www.helmholtz-hzi.de/en/media-center/newsroom/news-detail/an-unexpected-...
Helmholtz Institute for RNA-based Infection Research:
The Helmholtz Institute for RNA-based Infection Research (HIRI) is the first institution of its kind worldwide to combine ribonucleic acid (RNA) research with infection biology. Based on novel findings from its strong basic research program, the institute’s long-term goal is to develop innovative therapeutic approaches to better diagnose and treat human infections. HIRI is a site of the Braunschweig Helmholtz Centre for Infection Research (HZI) in cooperation with the Julius-Maximilians-Universität Würzburg (JMU) and is located on the Würzburg Medical Campus. More information at https://www.helmholtz-hiri.de.
Helmholtz Centre for Infection Research:
Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body’s defence mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases. https://www.helmholtz-hzi.de/en
Media contact:
Luisa Härtig
Manager Communications
Helmholtz Institute for RNA-based Infection Research (HIRI)
Josef-Schneider-Str. 2 / D15
97080 Würzburg | Germany
+49 931 31 86688
luisa.haertig@helmholtz-hiri.de
Cosi V, Jung J, Popella L, Ponath F, Ghosh C, Barquist L, Vogel J (2025) An antisense oligomer conjugate with unpredicted bactericidal activity against Fusobacterium nucleatum. mBio, DOI: 10.1128/mbio.00524-25
https://doi.org/10.1128/mbio.00524-25
Electron microscope image of Fusobacteria
HZI/Mathias Müsken
Merkmale dieser Pressemitteilung:
Journalisten, Wissenschaftler
Biologie, Medizin
überregional
Forschungsergebnisse, Wissenschaftliche Publikationen
Englisch
Electron microscope image of Fusobacteria
HZI/Mathias Müsken
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
